H. Long

发表

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study

B. Monk, Jubilee Brown, H. Michael, 2015, Clinical Cancer Research.

Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.

B. Monk, L. Ramondetta, H. Michael, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy in cervix cancer: is it effective?

H. Long, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980.

S. Cha, G. Malkasian, H. Long, 1989, Gynecologic oncology.

Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183.

R. McGhee, H. Hricak, L. Schwartz, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

B. Monk, C. Tian, D. Moore, 2010, Gynecologic oncology.

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies.

D. Moore, H. Long, S. Plaxe, 2008, American journal of obstetrics and gynecology.

Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183.

H. Hricak, D. Mitchell, D. Chi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.

Tina A. Ayeni, A. Weaver, A. Mariani, 2013, Gynecologic oncology.

Chapter 9 – Treatment of Recurrent Vaginal, Vulvar, and Cervical Cancer

H. Cárdenes, M. Randall, D. Moore, 2004 .

Current research directions for locally advanced cervix cancer

H. Long, 2003, Current oncology reports.

Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.

L. Hartmann, K. Podratz, S. Dowdy, 2002, American journal of obstetrics and gynecology.

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

B. Monk, D. Cella, Helen Q. Huang, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.

S. Arbuck, H. Averette, S. Wadler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.

D. Ahmann, E. Creagan, S. Frytak, 1986, Cancer treatment reports.

Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy

J. Ingle, C. Loprinzi, J. Krook, 1994, Cancer.

A double‐blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the north central cancer treatment group and mayo clinic

D. Schaid, J. Ingle, C. Loprinzi, 1991, Cancer.

A Randomized Trial of Cyclophosphamide, Doxorubicin, and Prednisone Versus Cyclophosphamide, 5‐Fluorouracil, and Prednisone in Patients with Metastatic Breast Cancer

D. Schaid, J. Buckner, J. Ingle, 1991, American journal of clinical oncology.

Randomized Trial of Doxorubicin Alone or Combined with Vincristine and Mitomycin C in Women with Metastatic Breast Cancer

D. Schaid, J. Ingle, J. Krook, 1989, American journal of clinical oncology.

Granulocyte‐macrophage colony‐stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin

L. Hartmann, J. Edmonson, J. A. Jefferies, 1992, Cancer.

Factors Associated With Grade 3 or 4 Treatment-Related Toxicity in Women With Advanced or Recurrent Cervical Cancer: An Exploratory Analysis of NRG Oncology/Gynecologic Oncology Group Trials 179 and 204

B. Monk, D. Cella, L. Ramondetta, 2015, International Journal of Gynecologic Cancer.

From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.

L. Hartmann, W. Cliby, G. Aletti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.

R. Goldberg, J. Kugler, R. Levitt, 1994, Gynecologic oncology.

Evaluation of treatment and survival after positive second-look laparotomy.

H. Wieand, G. Malkasian, J. A. Jefferies, 1988 .

Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.

J. Kugler, K. Rowland, V. Suman, 2006, Gynecologic oncology.

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

D. Miller, J. Fiorica, J. Sorosky, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient Reported Outcomes in a Practice Changing Randomized Trial of Bevacizumab in the Treatment of Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

L. Ramondetta, H. Michael, M. Method, 2015 .

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

B. Monk, D. Miller, J. Fiorica, 2006, Gynecologic oncology.

Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.

M. J. Webb, J. Kugler, H. Wieand, 1995, Gynecologic oncology.

Second-line and subsequent therapy for ovarian carcinoma

P. Peethambaram, H. Long, 2002, Current oncology reports.

Localized ovarian cancer in the elderly: The gynecologic oncology group experience

H. Averette, M. Brady, R. Young, 2010, Cancer.

Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study

B. Monk, L. Ramondetta, H. Michael, 2013 .

Evaluation of treatment and survival after positive second‐look laparotomy

J. Edmonson, G. Malkasian, J. A. Jefferies, 1989, Gynecologic oncology.

Primary leptomeningeal presentation of T‐cell lymphoma: Report of a patient and review of the literature

W. Marsh, H. Long, Dennis R. Stevenson, 1983, Cancer.

Phase II evaluation of L‐alanosine (NSC‐153353) for patients with disseminated malignant melanoma

D. Ahmann, S. Green, E. Creagan, 1984, American journal of clinical oncology.

Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis

D. Schaid, J. Ingle, J. Krook, 1991, Cancer.

Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature

K. Podratz, J. Bakkum-Gamez, H. Long, 2012, The journal of obstetrics and gynaecology research.

Lack of Value for Cisplatin Added to Mitomycin‐Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized Trial

T. Therneau, J. Rubin, A. Schutt, 1987, American journal of clinical oncology.

Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.

H. Long, 1994, Mayo Clinic proceedings.

A phase II evaluation of menogaril in cisplatin‐refractory advanced ovarian carcinoma. A collaborative trial of the north central cancer treatment group and the mayo clinic

J. Laurie, J. Krook, J. Edmonson, 1991, Cancer.

Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency.

J. Buckner, J. Edmonson, T. Fitch, 1989, Journal of the National Cancer Institute.

Phase II evaluation of carboplatin in advanced endometrial carcinoma.

J. Buckner, J. Edmonson, H. Wieand, 1988, Journal of the National Cancer Institute.

QUALITY OF LIFE OUTCOMES FROM GOG 179: A PHASE III TRIAL OF CISPLATIN VS CISPLATIN/TOPOTECAN IN RECURRENT OR PERSISTENT CARCINOMA OF THE CERVIX

B. Monk, D. Cella, H. Huang, 2004, International Journal of Gynecologic Cancer.

RANDOMIZED PHASE III TRIAL OF CISPLATIN VS CISPLATIN PLUS TOPOTECAN VS THE COMBINATION OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (MVAC) IN STAGE IVB, RECURRENT OR PERSISTENT CARCINOMA OF THE UTERINE CERVIX: A GYNECOLOGIC ONCOLOGY GROUP STUDY

D. Miller, J. Sorosky, J. Benda, 2004, International Journal of Gynecologic Cancer.

Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas

S. Green, J. Edmonson, E. Creagan, 2004, Cancer Chemotherapy and Pharmacology.

Phase II study of recombinant leukocyte a interferon (rIFN‐αA) in disseminated malignant melanoma

D. Ahmann, S. Green, E. Creagan, 1984, Cancer.

Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?

L. Kvols, J. Edmonson, H. Long, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy?

L. Kvols, J. Edmonson, H. Long, 1994, Journal of the National Cancer Institute.

Improved survival with bevacizumab in advanced cervical cancer.

Michael W Sill, Helen Huang, B. Monk, 2014, The New England journal of medicine.

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

L. Hartmann, J. Sloan, J. Sloan, 2010, Cancer research.

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

M. Birrer, R. Alvarez, J. Boggess, 2010, Gynecologic oncology.

A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.

D. Cella, A. Montag, N. Spirtos, 2009, Gynecologic oncology.

Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.

J. O'fallon, D. Ahmann, S. Green, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention, diagnosis, and treatment of cervical cancer.

B. Gostout, H. Long, N. Laack, 2007, Mayo Clinic proceedings.

Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy.

C. Hook, H. Long, T. -. Lee, 1994, Mayo Clinic proceedings.

Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.

R. Alvarez, M. Varia, B. Bundy, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.

D. Schaid, J. Ingle, J. Mailliard, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.

J. Ingle, D. Ahmann, S. Green, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant leukocyte a interferon (rIFN‐αA) in the treatment of disseminated malignant melanoma: Analysis of complete and long‐term responding patients

D. Ahmann, E. Creagan, S. Frytak, 1986, Cancer.

Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas.

D. Schaid, J. Buckner, C. Loprinzi, 1989, Journal of the National Cancer Institute.

Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.

K. Rowland, H. Pitot, V. Suman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses

D. Ahmann, E. Creagan, S. Frytak, 1987, Cancer.

International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG).

Jacob C Lindegaard, Harry Long, William Small, 2012, International journal of radiation oncology, biology, physics.

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

B. Monk, L. Ramondetta, L. Landrum, 2015, The Lancet. Oncology.

Phase II clinical trial of the combination VP-16, bleomycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive squamous cell carcinoma.

E. Creagan, J. Rubin, M. Chang, 1987, Head & neck surgery.

A phase II clinical trial of the combination mitomycin C, adriamycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive cancer.

E. Creagan, J. Rubin, M. Chang, 1986, Head & neck surgery.

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.

B. Monk, D. Cella, L. Wenzel, 2012, Gynecologic oncology.

Management of metastatic cervical cancer: review of the literature.

H. Long, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

A. Oberg, L. Hartmann, E. Galanis, 2015, Cancer research.

Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma.

D. Ahmann, S. Green, E. Creagan, 1984, Cancer.

Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma.

D. Ahmann, S. Green, E. Creagan, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study

B. Monk, Jubilee Brown, R. Mannel, 2017, British Journal of Cancer.

Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer.

J. Kovach, E. Creagan, R. Richardson, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?

W. Cliby, K. Podratz, G. Aletti, 2007, Gynecologic oncology.

Comparison of Conventional Dose and Double Dose Carboplatin in Patients Receiving Cyclophosphamide Plus Carboplatin for Advanced Ovarian Carcinoma: A North Central Cancer Treatment Group Study

J. Krook, V. Suman, J. Edmonson, 2001, Cancer investigation.

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.

D. Alberts, M. Brady, R. Young, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

L. Hartmann, F. Boakye-Agyeman, A. Chen, 2017, Clinical Cancer Research.

Long-Term Survival of Patients With Advanced/Recurrent Carcinoma of Cervix and Vagina After Neoadjuvant Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without the Addition of Molgramostim, and Review of the Literature

L. Hartmann, S. Nair, V. Suman, 2002, American journal of clinical oncology.

Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.

J. A. Jefferies, J. Edmonson, G. McCormack, 1987, Cancer treatment reports.

High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy.

T. Lesnick, A. Mariani, K. Podratz, 2004, Gynecologic oncology.

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

L. Hartmann, M. J. Webb, J. Edmonson, 1992, Investigational New Drugs.

Recombinant leukocyte a interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma

E. Creagan, S. Frytak, C. Moertel, 1988, Cancer.

Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.

S. Green, E. Creagan, A. Schutt, 1986, Medical and pediatric oncology.

Phase II study of recombinant gamma-interferon in patients with advanced nonosseous sarcomas.

J. Edmonson, E. Creagan, S. Frytak, 1987, Cancer treatment reports.

Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas.

J. Edmonson, S. Frytak, L. Itri, 1987, Cancer treatment reports.

An unusual presentation of breast cancer in a very young woman

Kiley J. Johnson, A. Degnim, H. Long, 2011, BMJ Case Reports.

Identification of germline 185delAG BRCA1 mutations in non‐Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado

H. Long, 2004, Cancer.

Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.

D. Ahmann, E. Creagan, S. Frytak, 1987, Cancer treatment reports.

Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.

S. Cha, J. Krook, M. Veeder, 1995, Gynecologic Oncology.

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma

R. Advani, L. Hartmann, B. Sikic, 2004 .

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

R. Advani, L. Hartmann, B. Sikic, 2004, Cancer.

Neo-Adjuvant M-VAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin) chemotherapy for locally advanced or metastatic cervical and vaginal cancer

L. Hartmann, K. Podratz, H. Long, 1994 .

Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.

J. Sorosky, J. Blessing, H. Long, 2005, Gynecologic Oncology.

Phase II evaluation of menogaril in patients with advanced hypernephroma

T. Therneau, J. Buckner, R. Hahn, 1991, Investigational New Drugs.

Improved survival with bevacizumab in advanced cervical cancer.

B. Monk, L. Ramondetta, L. Landrum, 2014, The New England journal of medicine.

Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: A Gynecologic Oncology Group (GOG) study

B. Monk, L. Ramondetta, L. Landrum, 2014 .

High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study

B. Monk, L. Ramondetta, L. Landrum, 2014 .

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

L. Hartmann, J. Sloan, E. Galanis, 2010, Cancer research.

Phase II evaluation of menogaril in patients with advanced cervical carcinoma

R. Goldberg, G. Malkasian, J. Laurie, 1991, Investigational New Drugs.